Intelligence Feed event · Equity · 2026-10-20

    Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMS

    Question

    Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMS

    Direct answer

    Oculis scheduled a late-breaking oral presentation of plasma NfL and GFAP biomarker results from its Phase 2 ACUITY clinical study. The presentation will take place at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, running October 21 to 23, 2026. The data evaluate Privosegtor for patients experiencing acute optic neuritis, focusing on biomarker endpoints associated with neuroprotection. Favorable biomarker shifts would support progression toward pivotal phase development.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-20
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMS”, revision 1, evidence through 2026-10-20. https://marketontology.com/market-events/2026-10-20/oculis-to-present-phase-2-acuity-trial-biomarker-results-at-actrims-ectrims-77a483

    EQUITY
    Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMS
    Oculis scheduled a late-breaking oral presentation of plasma NfL and GFAP biomarker results from its Phase 2 ACUITY clinical study. The presentation will take place at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, running October 21 to 23, 2026. The data evaluate Privosegtor for patients experiencing acute optic neuritis, focusing on biomarker endpoints associated with neuroprotection. Favorable biomarker shifts would support progression toward pivotal phase development.
    OCS
    Impact
    66
    OCT 20
    SIG
    85%
    OCS
    Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMS
    Oculis scheduled a late-breaking oral presentation of plasma NfL and GFAP biomarker results from its Phase 2 ACUITY clinical study. The presentation will take place at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, running October 21 to 23, 2026. The data evaluate Privosegtor for patients experiencing acute optic neuritis, focusing on biomarker endpoints associated with neuroprotection. Favorable biomarker shifts would support progression toward pivotal phase development.
    → Biomarker evidence of neuroaxonal preservation via plasma NfL reductions de-risks Privosegtor development, impacting OCS equity valuation.
    Impact
    Oculis scheduled a late-breaking oral presentation of plasma NfL and GFAP biomarker results from its Phase 2 ACUITY clinical study. The presentation will take place at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, running October 21 to 23, 2026. The data evaluate Privosegtor for patients experiencing acute optic neuritis, focusing on biomarker endpoints associated with neuroprotection. Favorable biomarker shifts would support progression toward pivotal phase development.
    Affected
    OCS
    Transmission
    Biomarker evidence of neuroaxonal preservation via plasma NfL reductions de-risks Privosegtor development, impacting OCS equity valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSclinical pipeline de-risking via plasma biomarker endpointsUp1-5dOculis scheduled presentation of Phase 2 ACUITY biomarker data at ACTRIMS-ECTRIMS on October 21-23.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month